Mustang Bio, Inc. (MBIO) stock
MBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.38−0.01 (-2.56%)
Close on Nov 18, 2026Market cap $2.88MP/E –Yield –
Mustang Bio r&d expenses
Research and development expenses are spending on new products and technology.
Mustang Bio's R&D Expenses for the twelve months ending Sep 30, 2024 was $14.37M, down 71.2% year over year. For fiscal 2024 it was $7.56M, down 81.3% from the year before. The highest annual figure on record is $62.48M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $7.56M | -81.3% |
| FY2023 | Dec 31, 2023 | $40.51M | -35.2% |
| FY2022 | Dec 31, 2022 | $62.48M | +25.3% |
| FY2021 | Dec 31, 2021 | $49.86M | +33.9% |
| FY2020 | Dec 31, 2020 | $37.24M | +23.9% |
| FY2019 | Dec 31, 2019 | $30.04M | +42.4% |
| FY2018 | Dec 31, 2018 | $21.10M | +165.7% |
| FY2017 | Dec 31, 2017 | $7.94M | +221.8% |
| FY2016 | Dec 31, 2016 | $2.47M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2024 | Sep 30, 2024 | $57.00K | -99.4% |
| Q2 FY2024 | Jun 30, 2024 | $4.36M | -59.8% |
| Q1 FY2024 | Mar 31, 2024 | $3.80M | -72.8% |
| Q4 FY2023 | Dec 31, 2023 | $6.15M | -60.6% |
| Q3 FY2023 | Sep 30, 2023 | $9.53M | -38.2% |
| Q2 FY2023 | Jun 30, 2023 | $10.84M | -28.5% |
| Q1 FY2023 | Mar 31, 2023 | $14.00M | -14.1% |
| Q4 FY2022 | Dec 31, 2022 | $15.60M | +17.7% |
| Q3 FY2022 | Sep 30, 2022 | $15.42M | +9.5% |
| Q2 FY2022 | Jun 30, 2022 | $15.16M | +39.1% |
| Q1 FY2022 | Mar 31, 2022 | $16.29M | +40.2% |
| Q4 FY2021 | Dec 31, 2021 | $13.26M | +31.2% |
| Q3 FY2021 | Sep 30, 2021 | $14.08M | +76.3% |
| Q2 FY2021 | Jun 30, 2021 | $10.90M | +10.9% |
| Q1 FY2021 | Mar 31, 2021 | $11.62M | +24.7% |
| Q4 FY2020 | Dec 31, 2020 | $10.11M | +12.9% |
| Q3 FY2020 | Sep 30, 2020 | $7.99M | +9.3% |
| Q2 FY2020 | Jun 30, 2020 | $9.83M | +44.1% |
| Q1 FY2020 | Mar 31, 2020 | $9.31M | +33.8% |
| Q4 FY2019 | Dec 31, 2019 | $8.95M | +12.7% |
| Q3 FY2019 | Sep 30, 2019 | $7.31M | +37.5% |
| Q2 FY2019 | Jun 30, 2019 | $6.82M | +91.8% |
| Q1 FY2019 | Mar 31, 2019 | $6.96M | +62.2% |
| Q4 FY2018 | Dec 31, 2018 | $7.94M | +210.7% |
| Q3 FY2018 | Sep 30, 2018 | $5.32M | +143.0% |
| Q2 FY2018 | Jun 30, 2018 | $3.56M | +42.6% |
| Q1 FY2018 | Mar 31, 2018 | $4.29M | +507.9% |
| Q4 FY2017 | Dec 31, 2017 | $2.56M | +163.9% |
| Q3 FY2017 | Sep 30, 2017 | $2.19M | +337.6% |
| Q2 FY2017 | Jun 30, 2017 | $2.49M | – |
| Q1 FY2017 | Mar 31, 2017 | $706.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $968.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $500.00K | – |
See a number that looks wrong?